WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that sanofi-aventis has exercised its option under a 2006 agreement for expanded access to ImmunoGen’s Tumor-Activated Prodrug (TAP) technology.
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that sanofi-aventis has exercised its option under a 2006 agreement for expanded access to ImmunoGen’s Tumor-Activated Prodrug (TAP) technology.
